LarryDAndersonJr.MDPhD, FACP

Hematologic Oncology

Professor, Cellular Therapy and Hematologic Malignancies, Director of Myeloma, Waldenstrom's & Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

Join to view full profile

Dr. Anderson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Anderson's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2661
Is this information wrong?

Summary

Dr. Larry Anderson is a hematologist in Dallas, TX and is affiliated with University of Texas Southwestern Medical Center and William P. Clements, Jr. University Hospital. He received his MD from University of Texas Medical School Houston, PhD from MD Anderson Cancer Center/GSBS, internal medicine residency at Mayo Clinic Rochester, and Oncology fellowship at Fred Hutchinson Cancer Research Center/University of Washington. He has been in practice 14 years. He specializes in plasma cell disorders and is experienced in bone marrow transplantation, multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Washington School of MedicineFellowship, Oncology/Bmt, 2003 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
McGovern Medical School at UTHealthClass of 2000

Certifications & Licensure

TX State Medical License 2008 - 2025
WA State Medical License 2003 - 2010
MN State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Best Doctors D Magazine, 2021-2023
Texas Super Doctors Texas Monthly Magazine, 2018-2023
Man of the Year Leukemia & Lymphoma Society North Texas, 2015
Who's Who in Healthcare Dallas Business Journal, 2015
Texas Super Doctor Rising Star Texas Monthly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Join now to see all

Clinical Trials

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Sep 15
Completed
Phase 1
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy Start of enrollment: 2020 Oct 05
Active, not recruiting
Phase 2
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Start of enrollment: 2018 Dec 13
Recruiting
Phase 2
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) Start of enrollment: 2020 May 27
Completed
Phase 1
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Available
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 3
Longterm Follow-up of Subjects Treated With bb2121 Start of enrollment: 2016 Apr 28
Completed
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Start of enrollment: 2024 Feb 15
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Lauren C Peres, Laura B Oswald, Christen M Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J Blue, Ciara L Freeman, Frederick L Locke, Melissa Alsina, Omar Castane...> ;Blood Advances. 2024 Jan 9
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hi...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengas...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmber...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Olalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, Tania Jain, Frederick L Locke, Linda Ramsdell, Sarah Nikiforow, Hamza Hashmi, Kathy Mooney, Shakthi T Bha...> ;Transplantation and Cellular Therapy. 2024 Feb 1
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
Banerjee R, Wang B, Anderson LD, McCaughan G, Mehra N, Cowan AJ, Rajkumar SV, Kaur G> ;Blood cancer journal. 2023-11-06
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy...
Anderson LD, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, Perales MA, Pasquini MC> ;Transplantation and cellular therapy. 2023-10-31
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunother...
Hashmi, H., Hansen, D., Peres, L., Puglianini, O., Freeman, C., De Avila, G., Sidana, S., Shune, L., Sborov, D., Davis, J., Wagner, C., Kocoglu, M., Atrash, S., Voorhe...> ;Haematologica. 2023 Oct 19
5 citations
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final ana...
Voorhees, P., Sborov, D., Laubach, J., Kaufman, J., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L., Anderson, L., Nathwani, N., Shah, N., Bumma, N., E...> ;The Lancet. Haematology. 2023 Oct 1
Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States.
Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD, D'Souza A> ;Bone marrow transplantation. 2023-09-06
3 citations
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson Jr., Jesús G Berdeja, Sagar Lonial, Noopur S Raj...> ;Blood Cancer Discovery. 2023 Sep 1
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, ...> ;Blood cancer journal. 2023-08-09
Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19.
Ruifang Zheng, Kelsey Mieth, Christen Bennett, Larry D Anderson Jr, Mingyi Chen, Jing Cao, Miller, C.> ;Cancers. 2023 Jul 13
11 citations
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Nav...> ;Blood Advances. 2023 Jun 27
Editorial: T-cell directed therapies in multiple myeloma.
Richter J, Anderson LD, Ramasamy K, Rossi A> ;Frontiers in oncology. 2023-06-16
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the G...
Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS...> ;Future oncology (London, England). 2023-02-17
13 citations
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Re...
Benjamin A Derman, Ankit Kansagra, Jeffrey Zonder, Andrew T Stefka, David L Grinblatt, Larry D Anderson Jr, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major,...> ;JAMA Oncology. 2022 Sep 1
4 citations
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
Kansagra, A., Dispenzieri, A., Fraser, R., Estrada-Merly, N., Sidana, S., Nishihori, T., Hansen, D., Anderson, L., Banerjee, R., Bumma, N., Dhakal, B., Khouri, J., Lan...> ;Blood Advances. 2022 Jul 12
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
Premnath N, Chung SS, Weinberg OK, Ikpefan R, Pandey M, Kaur G, Geethakumari PR, Afrough A, Awan FT, Anderson LD, Vusirikala M, Collins RH, Chen W, Agathocleous M, Mad...> ;Leukemia research. 2022-12-21
13 citations
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, ...> ;Transplantation and Cellular Therapy. 2023 Mar 1
1 citations
Cardiovascular disease and chimeric antigen receptor cellular therapy.
Anjali Rao, Andrew Stewart, Mahmoud Eljalby, Praveen Ramakrishnan, Larry D Anderson Jr, Farrukh T Awan, Alvin Chandra, Srilakshmi Vallabhaneni, Kathleen Zhang, Vlad G ...> ;Frontiers in Cardiovascular Medicine. 2022 Jan 1
8 citations
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Cesar Rodriguez, Luciano J Costa, Ajai Chari, Rebecca Silbermann, Sarah A Holstein,...> ;British Journal of Haematology. 2022 Nov 1
Preface of the Special Issue "COVID-19 Infection and Hematological Malignancies".
Mingyi Chen, Larry D Anderson Jr> ;Cancers. 2022 Sep 16
13 citations
Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for...
Miguel-Angel Perales, Larry D Anderson Jr, Tania Jain, Saad S Kenderian, Olalekan O Oluwole, Gunjan L Shah, Jakub Svoboda, Mehdi Hamadani> ;Transplantation and Cellular Therapy. 2022 Sep 1
127 citations
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial, Noopur S Raje, Eva Medvedova, Philip L McCarthy, Edward N Libby, Peter M Voorhees, Rob...> ;The New England Journal of Medicine. 2022 Jul 14
Join now to see all

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine

Abstracts/Posters

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

Researchers Uncover Mutated Genes Involved in Lung Cancer; One Affects NonsmokersOctober 24th, 2017
International Women’s Day: Perspectives in Medicine, Nursing, and Fellowship from Richa Thakur, Nida Khan, Lauren Ghazal, and Gurbakhash KaurMarch 9th, 2024
A Pioneer in Plasma Cell DisordersMarch 7th, 2021
Join now to see all